MedTrace Logo

Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty

NCT01683955 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2023-04-03

No results posted yet for this study

Summary

This study aims to assess postoperative blood loss and transfusion rates in total hip replacement after one-time administration of topical tranexamic acid.

Conditions

  • Acute Blood Loss Anemia
  • Osteoarthritis, Hip

Interventions

DRUG

Tranexamic acid

Topical tranexamic acid (2g/100mL 0.9% saline)

DRUG

Placebo

100mL 0.9% sterile saline

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • Michael Laker, M.D. · Henry Ford Health Systems

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-01
Primary Completion
2013-11-03
Completion
2013-11-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683955 on ClinicalTrials.gov